Biomarkers that can detect Alzheimer's disease (AD) will be most helpful for patient care and proper clinical trial design. We seek to identify a plasma phospholipid biomarker panel, derived from brain phospholipids, which can identify AD, track disease progression and discriminate patients with AD from those with Parkinson's disease.
Because the prevalence of Alzheimer's disease (AD) is on the rise, it is a public health necessity that the disease be diagnosed at its earliest stage in a relatively non-invasive manner. Biomarkers that can detect neurodegenerative diseases would be most helpful for patient care and for proper clinical trial design. The current project seeks to define an optimal panel of brain lipids, with a focus on phospholipids, for the detection of AD and tracking disease progression.